GlassScriptPhysician profile
Karen L Kerman
NPI 1518911767
$1,234.26
in general payments reported to CMS, 2019-2025
23 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $127 · 2024: $501 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $13.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.77 |
| Education | $13.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $520.69 | 2023-2025 | |
| Tg Therapeutics, INC. | $127.56 | 2025 | |
| Abbvie INC. | $83.38 | 2024-2025 | |
| Emd Serono, INC. | $55.65 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $52.77 | 2024-2025 | |
| Celgene Corporation | $48.70 | 2023-2024 | Zeposia |
| Amgen INC. | $35.28 | 2025 | Uplizna |
| Argenx US, INC. | $28.48 | 2023 | Vyvgart |
| Ucb, INC. | $26.84 | 2024 | Rystiggo |
| Csl Behring | $26.81 | 2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $24.74 | 2025 | Ultomiris |
| Lundbeck LLC | $21.93 | 2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $21.44 | 2025 | Onpattro |
| Neuropace, INC. | $20.16 | 2023 | |
| Eisai INC. | $19.49 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $19.23 | 2025 | Qutenza |
| Ani Pharmaceuticals, INC. | $19.04 | 2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $17.11 | 2025 | Austedo Xr |
| Biogen, INC. | $16.89 | 2025 | Tysabri, Vumerity |
| Genentech USA, INC. | $16.72 | 2024 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Tanabe Pharma America, INC. | $16.27 | 2025 | Radicava |
| Kyowa Kirin, INC. | $15.08 | 2024 | Nourianz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Kerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.